<DOC>
	<DOCNO>NCT00043446</DOCNO>
	<brief_summary>The purpose study determine whether T900607-sodium effective safe treat ovarian cancer .</brief_summary>
	<brief_title>Study T900607-Sodium Previously Treated Patients With Ovarian Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically confirm diagnosis ovarian cancer Subjects must receive 12 regimen prior chemotherapy ( one contain paclitaxel ) At least 18 year age Bidimensionally measurable disease amenable CT scanning . At least one lesion must least 1 X 1 cm size . Karnofsky performance status least 70 % Estimated life expectancy least 12 week Females childbearing potential must negative pregnancy test agree use effective contraceptive Subject must able comply study procedure followup examination . Signed write informed consent Lab Values ( obtain â‰¤ 7 day prior study enrollment ) : ANC least 1.5x10e9/L , Platelet count least 100x10e9/L , Hemoglobin least 8.5 g/dL , Creatinine within 2 time upper limit normal AST ALT within 3 time upper limit normal Bilirubin within 1.5 time upper limit normal Albumin great 2.5 g/dL INR &lt; 1.5 subject without anticoagulant Exclusion Criteria Severe , concurrent disease , infection comorbidity , judgment investigator , would make subject inappropriate enrollment NYHA Class III/IV cardiac disease , leave ventricular ejection fraction ( LVEF ) &lt; 50 % , acute anginal symptom Patients receive investigational agent within 4 week enrollment Patients pregnant breastfeed History prior malignancy ovarian cancer within last 5 year , except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix History central nervous system metastases carcinomatous meningitis Major surgery within 4 week enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
</DOC>